Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
Critical Reviews in Oncology/Hematology|January 21, 2023
Optimizing benefit/risk in oncology: Review of post-marketing dose optimization and reflections on the road aheadPooneh Soltantabar, Hoi-Kei Lon, Kourosh Parivar, et al.
Journal of Clinical Pharmacology|July 22, 2009
Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trialsDiane D Wang, Shuzhong Zhang, Hong Zhao, et al.
Targeted Oncology|November 19, 2020
Impact of Dose Reduction on Efficacy: Implications of Exposure-Response Analysis of PalbociclibJenny Zheng, Yanke Yu, Chandrasekar Durairaj, et al.
CPT: Pharmacometrics & Systems Pharmacology|October 5, 2023
Case-control matching-guided exposure-efficacy relationship for avelumab in patients with urothelial carcinomaPooneh Soltantabar, Ali Alhadab, Jennifer Hibma, et al.
Journal of Clinical Pharmacology|May 30, 2020
Talazoparib Exposure-Efficacy Analysis in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA TrialYanke Yu, Mohamed Elmeliegy, Jennifer K Litton, et al.
Regulatory Toxicology and Pharmacology : RTP|February 17, 2009
A comparison of effects on reproduction and neonatal development in cynomolgus monkeys given human soluble IL-4R and mice given murine soluble IL-4RLinda L Carlock, Laine A Cowan, Satoru Oneda, et al.
Journal of Clinical Pharmacology|November 26, 2013
Utility of population pharmacokinetic modeling in the assessment of therapeutic protein-drug interactionsAndrew T Chow, Justin C Earp, Manish Gupta, et al.
Journal of Clinical Pharmacology|May 30, 2020
Exposure-Safety Analyses of Talazoparib in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA and ABRAZO TrialsMohamed Elmeliegy, Yanke Yu, Jennifer K Litton, et al.
Pageof 3